Daiichi Sankyo Company, Limited

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-06-11 am EDT			5-day change	1st Jan Change
2,495.00 ^JPY	+0.30%		-0.87%	-25.48%

Jun. 05	Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca	AN
Jun. 03	Leica Biosystems, AstraZeneca , and Daiichi Sankyo Expand Collaboration to Scale Precision Medicine and Develop AI -Powered Diagnostics	CI

Breast Cancer Treatment from Daiichi Sankyo, AstraZeneca Approved in U.S.

Published on 05/15/2026 at 05:00 pm EDT

Dow Jones

DAIICHI SANKYO COMPANY, LIMITED

+0.30%

ASTRAZENECA PLC

+0.85%

By Katherine Hamilton

A drug developed by AstraZeneca and Daiichi Sankyo to treat breast cancer has been approved by the Food and Drug Administration.

Enhertu was approved for two new breast cancer indications for use before and after primary treatment in patients with Stage 2 or Stage 3 breast cancer, the companies said Friday.

The product was discovered by Daiichi and has been jointly developed and commercialized by both companies.

The approval was based on results of recent trials with positive results.

Following the approval in the U.S., AstraZeneca owes Daiichi $155 million in milestone payments for the positive early stage breast cancer indications.

Sales of Enhertu in the U.S. are recognized by Daiichi.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

05-15-26 1900ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Off-Hours Price	Change	5-day change	Capi.
	DAIICHI SANKYO COMPANY, LIMITED	2,495.00JPY	+0.30%	-0.87%	28.21B
	ASTRAZENECA PLC	13,578.00GBX	+0.85%	+0.18%	280B

Latest news about Daiichi Sankyo Company, Limited

Jun. 05	Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca	AN
Jun. 03	Leica Biosystems, AstraZeneca , and Daiichi Sankyo Expand Collaboration to Scale Precision Medicine and Develop AI -Powered Diagnostics	CI
May. 28	Daiichi Sankyo concludes pcpa letter of intent for Vanflyta®	RE
May. 28	Daiichi Sankyo Presents New Clinical Research And Product Pipeline Updates Across Oncology Portfolio At ASCO	CI
May. 26	AstraZeneca says Datroway approved in US for 1L triple-negative BC	RE
May. 22	FTSE 100 Closes Week Upbeat; AstraZeneca Sees Oncology Approval Progress	MT
May. 22	AstraZeneca Breast Cancer Drug Recommended for Approval by EU Regulator	DJ
May. 22	AstraZeneca and Daiichi cancer drugs clear regulatory hurdles	AN
May. 22	AstraZeneca, Daiichi Sankyo Win US FDA Approval for Datroway to Treat Triple-Negative Breast Cancer	MT
May. 22	AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Wins US FDA Approval	MT
May. 22	Daiichi Sankyo and Astrazeneca Announce Approval of Datroway as First Trop2 Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple Negative Breast Cancer in the U.S	CI
May. 22	AstraZeneca, Daiichi Sankyo's Enhertu Recommended for EU Approval for HER2-Positive Solid Tumors	MT
May. 22	AstraZeneca, Daiichi Sankyo Win EU Panel's Recommendation for Metastatic Solid Tumors Therapy	MT
May. 22	Daiichi Sankyo and Astrazeneca Announce Enhertu's Recommendation for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors	CI
May. 22	EMA's CHMP recommends extension to marketing authorisation for Wegovy	RE

Chart Daiichi Sankyo Company, Limited

Duration

Period

4568: Dynamic Chart

Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.

Employees

19,765

Sector

Pharmaceuticals

More about the company